Biotech companies have always licensed programs, but never so many from one region in particular.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Biotech is producing scientific breakthroughs that once seemed impossible. But according to longtime industry executive Jeremy Levin, the institutions ...

Leading figures from artificial intelligence, biotechnology, and national security are urging governments to mandate ...

Jonathan Faison first started exploring the biotech space a decade ago. He emphasizes a focus on preserving capital by limiting position sizes and picking stocks that have multiple "irons in the fire" ...

The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R&D costs and long lead times for bringing new ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Mon, August 4, 2025 at 11:15 AM UTC Viking Therapeutics (NASDAQ: VKTX) represents exactly this type of overlooked opportunity, trading at a valuation of just $3.7 billion as of Aug. 1, despite owning ...